Radiation Myelitis After Hypofractionated Spine Stereotactic Body Radiation Therapy
This cohort study characterizes the risk of radiation myelitis after spine stereotactic body radiation therapy to update the current dosimetric constraints.
Related Articles
FDA Seeks to Remove Oral Phenylephrine From Decongestants
The US Food and Drug Administration (FDA) is considering removal of oral phenylephrine, a widely used ingredient to treat nasal congestion, from over-the-counter (OTC) cold…
Highlights of ASH in Asia-Pacific
Join the world’s leading hematology experts at Highlights of ASH in Asia-Pacific, a two-day program that highlights the most influential research presented at the latest…
AHNS Message From The President – American Head & Neck Society
Dear AHNS Members, As 2024 comes to a close, I am excited to share updates on our society’s progress over the last seven months…
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer
The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.
Help Fund an Early-Career Researcher
Eighty-eight cents of every dollar you give does directly to cancer research. Cancer Research Saves Lives.
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
PURPOSEThe use of anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CART) therapy for AL amyloidosis (AL) is limited owing to patient frailty. HBI0101 anti-BCMA…
Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
Key Points+1q is associated with worse hematologic response rate and heme-EFS with daratumumab-based frontline therapy in AL amyloidosis.t(11;14) is no lon
Leach’s Insights on Advancements and Challenges in SCLC Treatment
Joe Leach, MD, discusses how comprehensive biomarker testing has impacted treatment selection for patients with small cell lung cancer.
Dialysis Facility Staffing Ratios and Kidney Transplant Access Among Adolescents and Young Adults
This cohort study aims to determine whether patient to nurse or patient to social worker staff ratios are associated with access to kidney transplant for…
